• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH
Click for more information
0.00% 0.3¢

ALTERITY THERAPEUTICS LIMITED

Market Cap $15.96M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ATH
Meetings this year 		16:21 26 5.8K
16:21 Last post  Scottsmyname Comments Created with Sketch.  26  Views Created with Sketch.  5.8K 
ATH
Ann: Change of Director's Interest Notice - BM / PM 		20/09/24 0 254
20/09/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  254 
ATH
WTF !!!
2
20/09/24 61 17K
20/09/24 Last post  RebekahChambers Comments Created with Sketch.  61  Views Created with Sketch.  17K 
ATH
Amyloid clearance by monocytes correlates with AD progression 		18/09/24 9 2.2K
18/09/24 Last post  pivalde Comments Created with Sketch.  9  Views Created with Sketch.  2.2K 
ATH
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
2 3
16/09/24 169 48K
16/09/24 Last post  RebekahChambers Comments Created with Sketch.  169  Views Created with Sketch.  48K 
ATH
Plasma neurofilament light in PD 		10/09/24 0 313
10/09/24 Last post  pivalde Comments Created with Sketch.  0  Views Created with Sketch.  313 
ATH
Iron transporters in AD and PD 		09/09/24 0 249
09/09/24 Last post  pivalde Comments Created with Sketch.  0  Views Created with Sketch.  249 
ATH
Ann: Notification of cessation of securities - ATH 		04/09/24 25 5.7K
04/09/24 Last post  Scottsmyname Comments Created with Sketch.  25  Views Created with Sketch.  5.7K 

See All Discussions arrow Created with Sketch.

Timeline

Change of Director's Interest Notice - BM / PM
20 Sep 08:17
 
Notification of cessation of securities - ATH
02 Sep 11:41
 
Appendix 4E Preliminary Final Report
29 Aug 13:23
 
Notification of cessation of securities - ATH
01 Aug 08:35
 
Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 08:12
 
Alterity Therapeutics to Present at MST Financial Webinar
24 Jul 11:15
 
View More arrow Created with Sketch.

Featured News

NEWS $11.1M capital raise secured – CEO leads $1M push to fast-track alzheimers trial
right-arrow Created with Sketch.
EBR $50M capital raise to scale EBR’s WiSE® System – FDA approval expected in 2025
right-arrow Created with Sketch.
NEWS Breakthrough FDA response clears path for OA phase 3 trial – major milestone achieved!
right-arrow Created with Sketch.
(20min delay)
Last
0.3¢ 		Change
0.000(0.00%) 		Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $3.54K 1.169M

Buyers (Bids)

No. Vol. Price($)
62 82714032 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 281957 2
View Market Depth
Last trade - 15.59pm 20/09/2024 (20 minute delay) ?
Last
0.3¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
0.3¢ 0.3¢ 0.3¢ 1184327
Last updated 15.58pm 20/09/2024 ?
ATH (ASX) Chart

Top Stories

Catalina Resources kicks off aircore drilling at Laverton project on the hunt for gold, REEs

Catalina Resources has confirmed its latest drill run has kicked off on-site its Laverton Project in Western Australia's Northern Goldfields.
Harvey Norman hit with a second class action – and shareholders, once again, don't care Harvey Norman (ASX:HVN) has confirmed it's been hit by a second class action this week over allegedly dodgy warranty cover – and the stock is up +1.23 at 11.15am Sydney time.
Tennant Minerals clocks high-grade gold, copper hits at Bluebird in the NT Tennant Minerals has unveiled the results of its latest drill campaign at its Bluebird project, posting "high-grade" copper and gold hits.
Week 38 Wrap: US markets panic at 50bp cut; ALS’s minerals revenue  slowdown; RBA path unclear Well, it finally happened – the US Fed cut interest rates this week, and we got a double dose: a whole -50bps knocked off.
ASX Market Open: Aussie stocks follow US surge after Fed rate cut decision | September 20, 2024 Australia's stock market is set to open higher today, following record performances on Wall Street, following the Federal Reserve's rate cut

Featured News

EBR $50M capital raise to scale EBR’s WiSE® System – FDA approval expected in 2025
right-arrow Created with Sketch.
NEWS Breakthrough FDA response clears path for OA phase 3 trial – major milestone achieved!
right-arrow Created with Sketch.
NEWS $11.1M capital raise secured – CEO leads $1M push to fast-track alzheimers trial
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.